Highlights {#Sec1}
==========

Abnormal glucose metabolism is common in ACS patients.Patients with definite diabetes have a doubled CV risk during the first year after an ACS event.However, prediabetes is not immediately associated with worse CV outcomes during up to one year of follow up.Although prediabetes is important to diagnose, the CV risk is not increased, compared with normoglycemic patients, during the first year after ACS.

Introduction {#Sec2}
============

Diabetes mellitus (DM) is associated with a two- to four-fold increased risk for cardiovascular (CV) events compared with non-diabetics \[[@CR1]\]. In patients without diagnosed DM, but with borderline increased haemoglobin A1c (HbA1c), heightened fasting glucose or abnormal glucose tolerance test, an increased risk of CV events has been observed in a general population \[[@CR2], [@CR3]\]. The impact of dysglycaemia on CV risk in patients with acute coronary syndrome (ACS) is less clear with partly conflicting results \[[@CR2]--[@CR10]\]. In the PLATelet inhibition and patient Outcomes (PLATO) trial, we evaluated the effect of the antiplatelet drug ticagrelor, compared to clopidogrel, in patients with ACS \[[@CR11], [@CR12]\]. We have previously reported ticagrelor to be both more efficacious and of similar safety compared with clopidogrel, irrespective of diabetes status \[[@CR8]\]. In the current substudy, we stratified patients into clinically accepted subgroups of glycaemia based on admission non-fasting glucose and HbA1c to explore the impact of dysglycaemia on CV outcomes \[[@CR3], [@CR8]\].

Methods {#Sec3}
=======

Study population {#Sec4}
----------------

The PLATO trial (NCT00391872) enrolled 18624 patients with ACS, who were randomised to either clopidogrel or ticagrelor treatment in addition to optimal medical therapy, including aspirin, and optional invasive strategy \[[@CR11], [@CR12]\]. All patients were evaluated for diabetes at baseline, and baseline non-fasting glucose concentration and HbA1c were collected. All participants provided written informed consent and the study complied with the declaration of Helsinki. The study was approved by all local Ethics Committees and Institutional Review Boards.

Laboratory analysis {#Sec5}
-------------------

The details of laboratory sampling and handling have previously been published \[[@CR11], [@CR12]\].

Plasma glucose and HbA1c concentrations were determined with sandwich immunoassays on the Cobas® Analytics e601 Immunoanalyzer (Roche Diagnostics, Mannheim, Germany) at the Uppsala Clinical Research Center laboratory, Uppsala, Sweden.

Definitions of outcome events and glycaemia subgroups {#Sec6}
-----------------------------------------------------

The primary endpoint of the present biomarker substudy was the composite of CV death, stroke or spontaneous myocardial infarction (sMI) within one year of follow up. sMI was defined in accordance with the universal definition of myocardial infarction (MI), hence a non-procedure-related, non-fatal, MI type 1 \[[@CR13]\].

DM was defined as patients with known diabetes or admission HbA1c ≥ 6.5% (≥ 48 mmol/mol), or non-fasting venous glucose ≥ 11.1 mmol/L on admission. Pre-DM was defined as patients with HbA1c ≥ 5.7% but \< 6.5% (≥ 39 mmol/mol but \< 48 mmol/mol) \[[@CR3]\]. Patients with HbA1c \< 5.7% were considered to have neither DM nor pre-DM (referred to here as 'non-diabetes') \[[@CR3]\].

Statistical analysis {#Sec7}
--------------------

Baseline characteristics were presented by subgroups of glycaemia, and compared using chi-square or Kruskal--Wallis tests. Kaplan Meier event rates at 1-year, overall and by glycaemic subgroups, were estimated. The associations between glycaemic subgroups, with the non-diabetes group as reference, and the outcomes were assessed by Cox proportional hazard models. Unadjusted and adjusted hazard ratios were derived. Adjustment variables included baseline characteristics (age, gender, smoking status, type of ACS, and history of angina, MI, hypercholesterolemia, diabetes, hypertension, chronic kidney disease, previous; percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG); stroke or transient ischemic attack (TIA), as well as log transformed biomarkers; NT-pro-BNP and hs-troponin I. p-values less than 0.05 were considered statistically significant results. Statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC) (Fig. [1](#Fig1){ref-type="fig"}).

Results {#Sec8}
=======

Information on previous DM, non-fasting glucose and/or HbA1c, were available for 16,007 patients (85.9%). On admission, 6160 patients (38.5%) had DM according to our pre-specified criteria, of which 1501 patients (9.4%) had no previous DM diagnosis, consequently new-onset DM. In the new-onset DM subgroup, 1076 patients had an HbA1c ≥ 6.5%. Another 201 individuals had non-fasting blood glucose above 11.1 mmol/L, but with normal HbA1c. A total of 224 patients had both an elevated HbA1c and non-fasting blood glucose above 11.1 mmol/L.

Patients with DM were older, and had more comorbidities compared to patients without DM (Table [1](#Tab1){ref-type="table"}). In patients with DM, normal HbA1c (\< 5.7%) was observed in 146 patients (2.4%), while HbA1c was between 5.7 and 6.4% in 811 patients (13.2%) and 4346 patients (70.5%) had an HbA1c of ≥ 6.5%. HbA1c was not available in 857 patients (13.9%) classified as diabetic by other criteria.

Table 1Baseline characteristics by glycemic subgroupsCharacteristicDiabetic\
(N = 6160)Pre-diabetic\
(N = 6210)Non-diabetic\
(N = 3637)Overall\
(N = 16,007)p-valueFemale gender2074 (33.7%)1703 (27.4%)854 (23.5%)4631 (28.9%)\< 0.0001Age, years (median, 25th--75th)64 (56--72)62 (54--71)60 (51--68)62 (54--71)\< 0.0001Weight, kg (median, 25th--75th)81.0 (70.0--92.0)80.0 (70.0--90.0)78.0 (68.0--86.0)80.0 (70.0--90.0)\< 0.0001Smoking status\< 0.0001 Non-smoker2794 (45.4%)2285 (36.8%)1273 (35.0%)6352 (39.7%) Ex-smoker1674 (27.2%)1481 (23.8%)875 (24.1%)4030 (25.2%) Habitual smoker1692 (27.5%)2444 (39.4%)1489 (40.9%)5625 (35.1%)Systolic blood pressure (mmHg)135 (120--150)130 (120--150)130 (120--149)133 (120--150)\< 0.0001Diastolic blood pressure (mmHg)80 (70--88)80 (70--90)80 (70--90)80 (70--90)0.0222*Medical history* Angina pectoris3211 (52.1%)2734 (44.0%)1361 (37.4%)7306 (45.6%)\< 0.0001 Myocardial infarction1565 (25.4%)1180 (19.0%)585 (16.1%)3330 (20.8%)\< 0.0001 Percutaneous coronary intervention1049 (17.0%)738 (11.9%)385 (10.6%)2172 (13.6%)\< 0.0001 Coronary artery bypass graft546 (8.9%)293 (4.7%)137 (3.8%)976 (6.1%)\< 0.0001 Non-haemorrhagic stroke324 (5.3%)206 (3.3%)99 (2.7%)629 (3.9%)\< 0.0001 Hypertension4827 (78.4%)3787 (61.0%)1977 (54.4%)10,591 (66.2%)\< 0.0001 Dyslipidaemia3389 (55.0%)2706 (43.6%)1446 (39.8%)7541 (47.1%)\< 0.0001 Peripheral artery disease514 (8.3%)335 (5.4%)165 (4.5%)1014 (6.3%)\< 0.0001 Chronic renal disease416 (6.8%)180 (2.9%)99 (2.7%)695 (4.3%)\< 0.0001*Treatment approach*\< 0.0001 Invasive4184 (67.9%)4489 (72.3%)2718 (74.7%)11,391 (71.2%)*Type of ACS*\< 0.0001 STEMI2183 (35.4%)2628 (42.3%)1582 (43.5%)6393 (39.9%)*Medications at the time of randomization* Aspirin5800 (94.2%)5834 (93.9%)3387 (93.1%)15021 (93.8%)0.1056 Beta blockers4307 (69.9%)4382 (70.6%)2545 (70.0%)11234 (70.2%)0.7072 ACE inhibitors3885 (63.1%)3400 (54.8%)186 (51.1%)9145 (57.1%)\< 0.0001 Angiotensin II receptor blockers764 (12.4%)445 (7.2%)247 (6.8%)1456 (9.1%)\< 0.0001 Statins4936 (80.1%)4978 (80.2%)2865 (78.8%)12,779 (79.8%)0.1904*Biochemistry (median, 25th--75th)* Creatinine clearance^a^ (mL/min)76.9 (58.8--96.5)80.8 (64.1--98.5)84.3 (67.2-102.3)80.4 (63.0--99.0)\< 0.0001 Glucose (mmol/L)9.3 (7.0--12.5)6.4 (5.6--7.5)6.1 (5.4--7.1)6.9 (5.7--8.8)\< 0.0001 Haemoglobin A1c (%)7.2 (6.5--8.5)5.9 (5.8--6.1)5.5 (5.3--5.6)6.0 (5.7--6.6)\< 0.0001 NT-proBNP (pmol/L)76 (24--244)53 (18--164)49 (17--147)59 (19--184)\< 0.0001 High sensitivity troponin I (ng/Lµg/L)2.0 (0.2--11.8)2.0 (0.2--12.0)2.2 (0.2--12.2)2.1 (0.2--12.0)0.4910^a^Cockcroft Gault

In addition, 6210 (38.8%) patients had pre-DM defined as HbA1c concentrations of ≥ 5.7% but \< 6.5%. Normal HbA1c concentrations (HbA1c \< 5.7%) were observed in 3637 (22.7%) of the study population.

Glycaemia subgroups and outcome {#Sec9}
-------------------------------

The Kaplan Meier event rates at 12 months for the combined endpoint of CV death, sMI or stroke per subgroups were 12.2% (694) for patients with DM, 7.2% (409) for pre-DM and 6.3% (213) for patients with no DM (Table [2 ](#Tab2){ref-type="table"}and Fig [1](#Fig1){ref-type="fig"}). In a sensitivity analysis, all MIs (not only sMI) were evaluated in the composite endpoint (CV death, MI and stroke), with event rates at 12 months per subgroups of 14.5% (832) for patients with DM, 9.0% (522) for pre-DM and 8.5% (293) for patients with no DM.

Fig. 1Kaplan Meier plots of the composite endpoint per glycemic subgroups

Table 2Proportions, event rates and hazard ratios (HR) per glycemic subgroupsDiabetesPre-diabetesNo diabetesProportion and number of patients38.5% (6160)38.8% (6210)22.7% (3637)  of which were new diagnosed9.4% (1501)Event rates at 12 months  CV death, sMI or stroke12.2% (694)7.2% (409)6.3% (213)  CV death6.9% (391)3.4% (195)3.0% (102)HR (95%CI)HR (95%CI)HR versus no diabetes CV death, sMI or stroke1.97 (1.69--2.29)1.12 (0.95--1.32)1  CV death2.30 (1.85--2.86)1.12 (0.88--1.42)1Adjusted HR vs no diabetes (n = 14,033)  CV death, sMI or stroke1.39 (1.11--1.74)1.02 (0.86--1.22)1  CV death1.92 (1.42--2.60)1.02 (0.79--1.32)1

The association between glycaemia subgroups and the combination of CV death, sMI or stroke is presented in Table [2](#Tab2){ref-type="table"}.

The Kaplan Meier event rates for CV death alone were: 6.9% (391), 3.4% (195) and 3.0% (102), with adjusted HRs presented in Table [2](#Tab2){ref-type="table"}.

The individual components of the composite endpoint were evaluated in secondary analysis and are presented in Table [2](#Tab2){ref-type="table"}.

Discussion {#Sec10}
==========

DM is independently associated with CV events, but there are conflicting reports on the impact of pre-DM on outcomes \[[@CR2]--[@CR7], [@CR9]\]. This may be due to differences in the identification, classification, follow-up and, in some cases, a lack of other important prognostic variables in ACS, including hs-troponin and NT-proBNP \[[@CR5]\]. DM is a multifaceted syndrome, and the pathogenesis for CV disease may include macrovascular changes, endothelial cell dysfunction and accelerated atherosclerosis, with a subsequent increased risk for plaque rupture, thrombus formation and ultimately vessel occlusion \[[@CR3]\].

In the current substudy, we found comorbidities to be more common in patients with DM, including disadvantageous biomarker levels such as elevated serum creatinine and NT-proBNP, indicating underlying organ dysfunction. We did not, however, observe any differences between patients with pre-DM and patients without DM.

Pre-DM, defined as blood glucose concentrations higher than normal but not meeting the definition of diabetes, is associated with an approximately 5--10% annual risk of developing type 2 DM \[[@CR14]\]. When diagnosed with DM, the patient momentarily is considered to have heightened risk for adverse events, and the indication for cardiac revascularisation, medical treatments e.g. ACE inhibitors, and fluid therapy with angiography uses the presence of DM as a dichotomous condition \[[@CR2], [@CR3], [@CR15]\]. It is, however, unknown if the observed heightened CV risk starts even at moderate levels of dysglycaemia or if abnormal glucose metabolism below a certain threshold may be non-pathogenic \[[@CR3], [@CR14]\].

In the current cohort, the proportion of patients with DM and at the same time a normal HbA1c was 2.5%, indicating that medical and lifestyle treatments still are not able to maintain normal HbA1c in patients with diabetes.

The increased CV risk for patients with manifest DM was, however, not observed in patients with pre-DM during the first year after ACS, and we believe this highlights that a direct effect of hyperglycaemia on clinical outcome may not be present, rather the deleterious hyperglycaemic effects may arise after a prolonged and accumulated exposure to dysglycemia.

Limitations {#Sec11}
-----------

Manifest DM was one of several enrichment criteria employed to enter the PLATO trial if presenting with a non-STEACS \[[@CR11], [@CR12]\]. It is likely that the current population exhibited a larger proportion of patients with diagnosed DM than other ACS populations, and consequently proportionally smaller subgroups of patients with pre-DM and no DM. Although follow up was up to one year, the detrimental effect of DM was not observed within the first year of diagnosis in the current study, however this study was not designed to answer these important questions.

Conclusions {#Sec12}
===========

Abnormal glucose metabolism is common in patients with ACS and 9% of the PLATO study patients had undiagnosed diabetes. Although the overall event rate during the first year after ACS is high, we only observed patients with definite DM to have a further increased CV risk, indicating that pre-DM is not immediately associated with worse CV outcomes over the first year after ACS. Nonetheless, this finding does not diminish the need for close follow-up of patients with pre-DM in order to detect DM early, as recommended by international guidelines.
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